Background: We previously demonstrated that adding venetoclax to reduced intensity conditioning (RIC) chemotherapy for patients undergoing alloHCT followed by maintenance therapy with intravenous azacitidine and venetoclax (Ven) was safe and associated with...
Background Leukemic stem cells have high expression of CD123 compared to normal hematopoietic stem cells. CD123 is therefore an attractive therapeutic target in myeloid neoplasms including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic...
IntroductionVenetoclax plus hypomethylating agents (VEN+HMA) has shown remarkable efficacy in elderly and unfit AML patients. However, prospective studies comparing VEN+HMA to standard intensive chemotherapy in young and fit AML patients are lacking. We conducted a...
BackgroundVenetoclax (ven) with azacitidine (aza) is the standard of care for newly diagnosed acute myeloid leukemia (AML) patients unfit for intensive chemotherapy (IC) due to age or comorbidities. However, fit patients with poor-risk disease biology may not benefit...
Disease relapse is the leading cause of death in patients undergoing RIC allo-HCT, affecting up to 40% of patients. TSC-100 and TSC-1001 are donor-derived T-cell receptor engineered T-cells designed to selectively eliminate residual disease cells post-HCT by targeting...
Despite recent advancements in the treatment of acute myeloid leukemia (AML) the outcome in the relapsed and refractory setting remains poor (Thol, Dohner et al. 2024). While the use of T cell engaging bispecific antibodies (TCE) targeting B cell lineage antigens such...
Recent Comments